Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Genes determining nevus count and dermoscopic appearance in Australian melanoma cases and controls.

Duffy DL, Jagirdar K, Lee KJ, McWhirter SR, McMeniman EK, De'Ambrosis B, Pflugfelder A, Rayner JE, Whiteman DC, Brown MA, Martin NG, Smithers BM, Schaider H, Soyer HP, Sturm RA.

J Invest Dermatol. 2019 Aug 14. pii: S0022-202X(19)32695-8. doi: 10.1016/j.jid.2019.05.032. [Epub ahead of print] No abstract available.

PMID:
31421127
2.

High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk.

Duffy DL, Lee KJ, Jagirdar K, Pflugfelder A, Stark MS, McMeniman EK, Soyer HP, Sturm RA.

Br J Dermatol. 2019 Mar 1. doi: 10.1111/bjd.17833. [Epub ahead of print]

PMID:
30820946
3.

GSTP1 does not modify MC1R effects on melanoma risk.

Daley GM, Duffy DL, Pflugfelder A, Jagirdar K, Lee KJ, Yong XLH, Eigentler TK, Weide B, Smithers BM, Martin NG, Garbe C, Soyer HP, Sturm RA.

Exp Dermatol. 2017 Aug;26(8):730-733. doi: 10.1111/exd.13114. Epub 2017 Mar 23. No abstract available.

PMID:
27304781
4.

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.

Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK.

EBioMedicine. 2015 May 12;2(7):671-80. doi: 10.1016/j.ebiom.2015.05.011. eCollection 2015 Jul.

5.

Left Atrial Appendage Closure -The WATCHMAN Device.

Akinapelli A, Bansal O, Chen JP, Pflugfelder A, Gordon N, Stein K, Huibregtse B, Hou D.

Curr Cardiol Rev. 2015 Nov 6;11(4):334-340. doi: 10.2174/1573403X11666150805115822.

6.

Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.

Wagner NB, Weide B, Reith M, Tarnanidis K, Kehrel C, Lichtenberger R, Pflugfelder A, Herpel E, Eubel J, Ikenberg K, Busch C, Holland-Letz T, Naeher H, Garbe C, Umansky V, Enk A, Utikal J, Gebhardt C.

Int J Cancer. 2015 Dec 1;137(11):2607-17. doi: 10.1002/ijc.29619. Epub 2015 Jul 14.

7.

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.

Ugurel S, Loquai C, Kähler K, Hassel J, Berking C, Zimmer L, Haubitz I, Satzger I, Müller-Brenne T, Mikhaimer NC, Becker JC, Kilian KJ, Schadendorf D, Heinzerling L, Kaatz M, Utikal J, Göppner D, Pföhler C, Pflugfelder A, Mössner R, Gutzmer R; Dermatologic Cooperative Oncology Group (DeCOG).

Ann Oncol. 2015 Mar;26(3):573-82. doi: 10.1093/annonc/mdu573. Epub 2014 Dec 18.

PMID:
25524477
8.

Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial.

Pflugfelder A, Andonov E, Weide B, Dirschka T, Schempp C, Stockfleth E, Stratigos A, Krüger-Krasagakis S, Bauer J, Garbe C, Eigentler TK.

Br J Dermatol. 2015 Apr;172(4):926-32. doi: 10.1111/bjd.13342. Epub 2015 Feb 25.

PMID:
25124939
9.

Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.

Zelba H, Weide B, Martens A, Derhovanessian E, Bailur JK, Kyzirakos C, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries J, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G.

Clin Cancer Res. 2014 Aug 15;20(16):4390-9. doi: 10.1158/1078-0432.CCR-14-1015. Epub 2014 Jun 17.

10.

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruffini PA, Elia G, Neri D, Gutzmer R, Becker JC, Garbe C.

Cancer Immunol Res. 2014 Jul;2(7):668-78. doi: 10.1158/2326-6066.CIR-13-0206. Epub 2014 Apr 4.

11.

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.

Meckbach D, Keim U, Richter S, Leiter U, Eigentler TK, Bauer J, Pflugfelder A, Büttner P, Garbe C, Weide B.

PLoS One. 2014 Feb 20;9(2):e89218. doi: 10.1371/journal.pone.0089218. eCollection 2014.

12.

Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma.

Meckbach D, Bauer J, Pflugfelder A, Meier F, Busch C, Eigentler TK, Capper D, von Deimling A, Mittelbronn M, Perner S, Ikenberg K, Hantschke M, Büttner P, Garbe C, Weide B.

PLoS One. 2014 Jan 24;9(1):e86194. doi: 10.1371/journal.pone.0086194. eCollection 2014.

13.

Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma".

Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D; German Dermatological Society; DermatologicCooperative Oncology Group.

J Dtsch Dermatol Ges. 2013 Aug;11 Suppl 6:1-116, 1-126. doi: 10.1111/ddg.12113_suppl. English, German.

PMID:
24028775
14.

S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.

Abusaif S, Jradi Z, Held L, Pflugfelder A, Weide B, Meier F, Garbe C, Eigentler TK.

Melanoma Res. 2013 Oct;23(5):396-401. doi: 10.1097/CMR.0b013e3283650741.

PMID:
23907232
15.

Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour.

Weide B, Faller C, Elsässer M, Büttner P, Pflugfelder A, Leiter U, Eigentler TK, Bauer J, Meier F, Garbe C.

PLoS One. 2013 Jun 25;8(6):e66953. doi: 10.1371/journal.pone.0066953. Print 2013.

16.

S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version.

Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D; German Society of Dermatology.

J Dtsch Dermatol Ges. 2013 Jun;11(6):563-602. doi: 10.1111/ddg.12044. No abstract available.

PMID:
23721604
17.

Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.

Weide B, Faller C, Büttner P, Pflugfelder A, Leiter U, Eigentler TK, Bauer J, Forschner A, Meier F, Garbe C.

PLoS One. 2013 Apr 29;8(4):e63137. doi: 10.1371/journal.pone.0063137. Print 2013.

18.

The role of radiotherapy in the overall treatment of melanoma.

Forschner A, Heinrich V, Pflugfelder A, Meier F, Garbe C.

Clin Dermatol. 2013 May-Jun;31(3):282-9. doi: 10.1016/j.clindermatol.2012.08.009. Review.

PMID:
23608447
19.

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.

Weide B, Elsässer M, Büttner P, Pflugfelder A, Leiter U, Eigentler TK, Bauer J, Witte M, Meier F, Garbe C.

Br J Cancer. 2012 Jul 24;107(3):422-8. doi: 10.1038/bjc.2012.306. Epub 2012 Jul 10.

20.

Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.

Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G.

J Clin Oncol. 2012 May 20;30(15):1835-41. doi: 10.1200/JCO.2011.40.2271. Epub 2012 Apr 23.

PMID:
22529253
21.

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, González-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E, Menssen HD, Neri D, Garbe C.

Clin Cancer Res. 2011 Dec 15;17(24):7732-42. doi: 10.1158/1078-0432.CCR-11-1203. Epub 2011 Oct 25.

22.

Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group.

Pflugfelder A, Welter AK, Leiter U, Weide B, Held L, Eigentler TK, Dirschka T, Stockfleth E, Nashan D, Garbe C; German Dermatologic Cooperative Oncology Group.

J Eur Acad Dermatol Venereol. 2012 Jan;26(1):48-53. doi: 10.1111/j.1468-3083.2011.04005.x. Epub 2011 Mar 18.

PMID:
21414035
23.

Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.

Pflugfelder A, Eigentler TK, Keim U, Weide B, Leiter U, Ikenberg K, Berneburg M, Garbe C.

PLoS One. 2011 Feb 16;6(2):e16882. doi: 10.1371/journal.pone.0016882.

24.

Thirty-year history of palmar eruptions: A quiz. Palmar purpuric lichen nitidus.

Ikenberg K, Pflugfelder A, Metzler G, Biedermann T.

Acta Derm Venereol. 2011 Jan;91(1):108-9. doi: 10.2340/00015555-0907. No abstract available.

25.

Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.

Weide B, Eigentler TK, Pflugfelder A, Leiter U, Meier F, Bauer J, Schmidt D, Radny P, Pföhler C, Garbe C.

Cancer Immunol Immunother. 2011 Apr;60(4):487-93. doi: 10.1007/s00262-010-0957-3. Epub 2010 Dec 21.

PMID:
21174093
26.

High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma.

Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, Pföhler C, Pawelec G, Garbe C.

Cancer. 2010 Sep 1;116(17):4139-46. doi: 10.1002/cncr.25156.

27.

Incisional biopsy and melanoma prognosis: Facts and controversies.

Pflugfelder A, Weide B, Eigentler TK, Forschner A, Leiter U, Held L, Meier F, Garbe C.

Clin Dermatol. 2010 May-Jun;28(3):316-8. doi: 10.1016/j.clindermatol.2009.06.013. Review.

PMID:
20541685
28.

Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies.

Leiter U, Eigentler TK, Forschner A, Pflugfelder A, Weide B, Held L, Meier F, Garbe C.

Clin Dermatol. 2010 May-Jun;28(3):311-5. doi: 10.1016/j.clindermatol.2009.10.001.

PMID:
20541684
29.

Melanoma staging: facts and controversies.

Forschner A, Eigentler TK, Pflugfelder A, Leiter U, Weide B, Held L, Meier F, Garbe C.

Clin Dermatol. 2010 May-Jun;28(3):275-80. doi: 10.1016/j.clindermatol.2009.06.012.

PMID:
20541679
30.

Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses.

Dirschka T, Bierhoff E, Pflugfelder A, Garbe C.

J Eur Acad Dermatol Venereol. 2010 Mar;24(3):258-63. doi: 10.1111/j.1468-3083.2009.03399.x. Epub 2009 Aug 26.

PMID:
19709346
31.

Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.

Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C.

J Immunother. 2009 Jun;32(5):498-507. doi: 10.1097/CJI.0b013e3181a00068.

PMID:
19609242

Supplemental Content

Loading ...
Support Center